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The second most serious neurodegenerative disease is Parkinson’s disease (PD). Over the past several decades, a
strong body of evidence suggests that PD can begin years before the hallmark clinical motor symptoms appear.
Biomarkers for PD are urgently needed to differentiate between neurodegenerative disorders, screen novel
therapeutics, and predict eventual clinical PD before the onset of symptoms. Some clinical evaluations and
neuroimaging techniques have been developed in the last several years with some success in this area. Moreover,
other strategies have been utilized to identify biochemical and genetic markers associated with PD leading to the
examination of PD progression and pathogenesis in cerebrospinal fluid, blood, or saliva. Finally, interesting results
are surfacing from preliminary studies using known PD-associated genetic mutations to assess potential premotor
PD biomarkers. The current review highlights recent advances and underscores areas of potential advancement.
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Parkinson’s Disease (PD) is a common and incapacitating
neurodegenerative disease which affects the human
population worldwide [1-3]. It generally presents clinic-
ally in adults over 60 years old, and major symptoms in-
clude akinesia, tremor, bradykinesia, and postural
instability. Currently, its diagnosis relies largely on as-
sessment of clinical symptoms. Unfortunately, this purely
clinical diagnosis, combined with the similarities of PD
symptoms with those of other neurodegenerative and
movement disorders, results in frequent misdiagnosis: up
to 50% of the time in primary care settings, while move-
ment specialists fare somewhat better with an early PD
misdiagnosis rate around 10% [4-6]. PD can currently
only be confirmed through its pathological hallmark of
Lewy bodies and Lewy neurites located in residual neu-
rons or axons, respecitively, upon postmortem analysis
[7]. To complicate matters, diagnosis is generally not
made until an advanced stage of neurodegeneration: by
some estimates, 50-60% of dopaminergic neurons in the
substatia nigra are lost prior to the time of clinical diag-
nosis [8-13], limiting effectiveness of potential* Correspondence: zhangj@u.washington.edu
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reproduction in any medium, provided the orneuroprotective therapies due to the low number of
remaining neurons (Figure 1).
Thus, introduction of new treatments and interven-
tions for PD will depend on improved diagnosis, prefer-
ably at early, premotor stages at which a larger
population of dopaminergic cells remains. Furthermore,
the progression of the disease must be accurately
assessed, in order to monitor efficacy of treatments and
improve individualized therapeutic strategies. Much
work toward this end has focused on identifying sensi-
tive, specific biomarkers for PD. According to the NIH
biomarker working group, a biomarker is “a characteris-
tic objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes or
pharmacological responses to a therapeutic interven-
tion”[14,15]. In other words, an ideal biomarker for PD
must be able to identify almost all cases of PD in its pre-
motor stages, change concomitantly with disease stages,
and differentiate between PD and other neurodegenera-
tive diseases. In practice, however, a combination of sev-
eral biomarkers will likely be needed to correctly
diagnose and track PD progression, and this review fo-
cuses on some of the most promising premotor PD bio-
markers which could be most effective.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Evolution of PD. During the course of normal aging (green line), small but slow dopaminergic degeneration occurs without any motor
symptoms. Typically idiopathic PD (iPD) (blue line) is of unknown origin but is thought to develop gradually over time with a slow degeneration
of dopaminergic neurons leading to the emergence of the classic PD motor symptoms later in life. Another model of dopamingeric
neurodegeneration leading to PD motor symptoms involves repeated exposure to environmental toxicants over time in combination with a
genetic predisposition to dopaminergic neuron loss (yellow line). Early-onset PD (red line), as caused by mutations in the parkin gene, involves a
precipitous decline in dopaminergic neuron number where PD motor symptoms can present decades prior to those in iPD. One more scenario
(not shown) of PD-motor symptom development involves possible in utero environmental toxicants or genetic factors leading to an atypically low
number of dopaminergic neurons at birth and increased susceptibility to PD development.
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Clinical biomarkers
It has been recognized recently that a variety of nonmo-
tor symptoms associated with PD may manifest years be-
fore the onset of motor symptoms. Indeed, these
premotor symptoms have been exploited in the last few
years as possible premotor biomarkers for PD. Though
not an exhaustive list, we focus here on some of the
most promising potential clinical premotor PD biomar-
kers, namely, rapid eye movement (REM) behavior dis-
order (RBD), bowel dysfunction, olfactory deficits, and
mood disorders.
It has been long observed that PD patients can have a
variety of sleep disturbances, most frequently manifest-
ing as RBD, which can precede the clinical motor symp-
toms associated with PD by several years [4,16-20]. In
fact, recent findings indicate that RBD is one of the
symptoms most strongly correlated with the presentation
of synucleinopathy (including multiple system atrophy
(MSA), PD, and dementia with Lewy bodies) later in life
[19,21].
Disruptions in bowel movements are another known
co-morbidity to PD. Much like RBD, constipation can
arise many years prior to the motor symptoms of PD
[22] and affects most PD patients [23]. Indeed, the fre-
quency of bowel movements was correlated inversely
with PD risk, and constipation may be one of the firstsymptoms of PD [22]. These findings were supported by
an additional epidemiological study involving women in
Olsmsted County, Minnesota, where an association be-
tween earlier life constipation and PD risk was well
documented [24]. Together, these reports document the
association of PD diagnosis with constipation symptoms
emerging as much as 20 years earlier.
Olfactory disruption is also a common symptom asso-
ciated with PD. Difficulties in detecting, discriminating,
and identifying odors are observed in up to 90% of PD
patients [25-27]. However, cross-sectional and longitu-
dinal studies of PD patients have frequently found olfac-
tory deficits to be largely uncorrelated with disease stage
or severity [28-31], leading to the hypothesis that olfac-
tory decline may occur largely prior to the onset of non-
motor symptoms. Indeed, as with constipation and sleep
disturbances, olfactory deficits can occur in the several
years leading up to motor impairments and clinical PD
diagnosis [25]. This idea is further supported by the find-
ing that, in recently diagnosed PD patients with mild
symptoms, severity of olfactory deficits has been found
to correlate with dopaminergic dysfunction as measured
by SPECT, despite a lack of correlation between either
measurement and severity of motor dysfunction [32-34].
To determine whether these early olfactory symptoms
might prove useful as a premotor biomarker for PD, a
number of studies have examined olfaction in early or
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shown that patients with poor olfaction were more likely
to develop PD in the 4-year follow up period than those
with normal olfaction [35]. Additionally, another study
found that when assessing asymptomatic first-degree
relatives of PD patients, performance levels of odor dis-
crimination robustly correlated with future PD risk [36].
Couple these studies with an initial report revealing that
olfactory identification dysfunction on the University of
Pennsylvania Smell Identification Test was able to distin-
guish PD from other movement disorders [26], and a
strong candidate for a clinical premotor PD biomarker
emerges.
Another potential clinical premotor PD biomarker is the
presence of mood alterations. Some of the most common
psychological symptoms associated with PD are depres-
sion, anxiety, and apathy [37]. Depression specifically is
thought to be biological component of the disease (as
opposed to a psychological reaction to the disease) as it is
detected in nearly a quarter of patients in the early stages
of PD [38,39]. Several groups have indicated that in the
later stages of PD, depression rates are approximately 40%,
but that this rate is probably grossly underestimated
[40,41]. Further, examination of historical medical records
at least 20 years before PD diagnosis led to the discovery
that anxiety was associated with the later incidence of PD
[42]. A few different groups have also speculated about a
possible parkinsonian personality that involved such traits
as inflexibility, neuroticism, obsessive-compulsivity, un-
easiness, and anxiety, among others [43-47]. These charac-
teristics are often present from childhood, leading to the
possibility of long lasting biological changes preceding PD
motor symptoms, and possibly implying that the observed
motor symptoms of PD are really characteristic of end-
stage disease. Supporting the idea that these symptoms are
a component of the disease are findings of alterations in
the serotonergic signaling pathways, long known to inter-
act with the classic dopaminergic neuronal degeneration
associated with PD and major target of anti-depressant
medications. For example, a major serotonergic nucleus,
the dorsal raphe, has enhanced cell loss in depressed PD
patients compared to non-depressed PD patients [48].
Moreover, recent studies have shown a reduction of gray
matter densities in the orbitofrontal cortex which are
known to be involved in serotonergic pathways responsible
for mood disorders [49,50]. Lewy body-related lesions also
have been found in raphe nucleus of early stage PD
patients and in asymptomatic individuals [51,52], further
implicating a serotonergic pathology in PD depression.
However, as with RBD, constipation, and anosmia, anxiety
and depression are very nonspecific, and do not stand
alone as clinical premotor PD biomarkers.
In short, a number of clinical symptoms appear years be-
fore the motor symptoms of PD. However, while each ofthe biomarkers occurs during premotor stages of PD, can
be measured, and tracked, none is specific enough to be
used alone as a premotor PD biomarker. As research pro-
gresses, the most likely role of these clinical premotor bio-
markers will be a supportive one, serving to confirm the
sensitivity and specificity of other premotor PD biomarkers.
Future work should also focus on using a combination of
clinical premotor biomarkers to enrich patient populations
for neuroimaging and biochemical screening and assess in
tandem multiple clinical symptoms for correlation for
developing PD later in life, along with coupling premotor
clinical signs with biochemical markers, neuroimaging, and
genetic testing (see below for more discussion on the topic).
Biochemical markers
Examination of various tissues and body fluids for the
relative levels of proteins and other molecules provides
information about the state of the local system, including
its metabolic state, disease condition, and response to
therapeutic treatments. Therefore, measurement of a
number of known small proteins and other molecules
along with unbiased profiling (recently reviewed else-
where [53,54]) is currently one of the most promising
avenues for potential premotor biomarkers of PD
(Table 1).
a. α-Synuclein α-synuclein has long been known to
form protein aggregates found in Lewy bodies, and has
been a major area of inquiry for PD treatments and bio-
marker discovery. Indeed, a consensus result of measur-
ing the different forms of the protein that accumulate in
cerebrospinal fluid (CSF), a body fluid in close proximity
and interaction with the central nervous system (CNS),
has started to emerge. Using both ELISA and Luminex
assays, several groups have examined α-synuclein in CSF
samples. These studies, which included large cohorts of
patients, have shown a reduction of α-synuclein levels in
CSF of PD patients offering a reasonable differential sen-
sitivity and specificity compared to healthy controls
[55,56]. However, there was no correlation between dis-
ease severity/duration and α-synuclein levels in these
investigations, in contrast to a previous report which also
detected reduced α-synuclein in the CSF of PD patients
[57]. Notably, in smaller scale investigations, while sev-
eral groups have also confirmed these observations
[56,58,59], others reported no discernible differences in
α-synuclein levels between control and PD patients
[60,61]. Many issues are potentially responsible for these
discrepancies, including sampling protocols, control for
blood contamination (see below) and differences in
detection/capture antibodies [62].
Because collection of CSF is somewhat invasive, mul-
tiple groups have investigated α-synuclein levels in other
tissues as PD biomarkers. Due to its ready accessibility,
Table 1 Summary of possible premotor PD biomarkers
Existing Biomakers Potential Biomakers Candidate biomakers
Uric acid a-sysnuclein DJ-1 SPECT fMRI PET Aβ42 tau
Blood 74–76 63 82





Structural Brain Elements 97–99
DAT Binding 88–90, 93, 94
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the results have been largely contradictory and inconclu-
sive [55,63-66]. A recent bright spot appears to be the
role of the concentrations of oligomeric α-synuclein in
plasma samples. El-Agnaf et al. discovered that the con-
centration of oligomeric forms was increased in PD
patients compared to controls [65]. They achieved high
specificity (85%) for the differentiation of PD patients
versus controls despite significant overlap of concentra-
tions with the control group [65]. Another group has re-
cently demonstrated significantly higher levels of auto-
antibodies towards monomeric α-synuclein in the blood
sera of PD patients compared to those from the control
group [67]. However, measurement of α-synuclein in
blood remains a significant problem, since >98% blood
based α-synuclein is contained in red blood cells, making
hemolysis, in vitro or in vivo, a major confounder in
these studies [55,68]. Therefore, potential biomarkers
based on blood α-synuclein remain either disappointing
or too preliminary to be clinically useful.
Several investigators are pursuing α-synuclein levels in
other tissue types as potential premotor PD biomarkers.
For example, one initial report has detected α-synuclein
in skin fibroblasts [69]. This group demonstrated that α-
synuclein levels are elevated in the skin fibroblasts of PD
patients compared to controls [69]. Although this study
involved a small number of subjects and has yet to be
replicated, using skin as a premotor biomarker has po-
tentially high value and utility as it is highly accessible
and can be procured without more invasive procedures.
Another promising line of evidence has emerged for
using α-synuclein as a premotor PD biomarker in human
saliva. Abnormal saliva production has been a long
shown to correlate with PD severity and known to be a
prevalent nonmotor symptom [70]. Del Tredici et al. re-
cently examined post-mortem PD, MSA, and control
submandibular glands for the presence of aggregated α-
synuclein [71]. They discovered the presence of Lewy
Body pathology by immunohistochemistry in the sub-
mandibular glands of all the PD cases examined, but notthe control or MSA cases [71] . Because the subman-
dibular glands respond to parasympathetic innervations
from the medulla [72], the cells responsible for saliva se-
cretion possess direct contact with the CNS. Therefore,
any saliva secreted from these glands may provide indir-
ect access to α-synuclein levels of the CNS. Saliva, as a
biological fluid, is completely accessible, can be obtained
without any invasive procedures, is readily available in
large quantities, and can be sampled virtually an unlim-
ited number of times from any individual. For these rea-
sons, we are currently investigating α-synuclein in saliva
as a biomarker. We are able to detect α-synuclein levels
in human saliva [73] and are investigating whether levels
of salivary α-synuclein differ between PD and healthy
controls. Clearly, this promising line of research will re-
quire independent validation from several groups before
its adaptation as a clinically useful biomarker.
b. Anti-oxidative stress makers Besides α-synuclein,
another major biochemical pathway dysregulated in PD
is the elevation of oxidative stress [74]. Accordingly, sev-
eral groups have explored oxidative stress metabolites,
such as uric acid [75], and proteins as PD biomarkers.
Three independent, large studies have indicated that
higher levels of uric acid in serum confer lower risk of
developing PD [76-78]. Additionally, the subset of diag-
nosed PD patients with higher uric acid levels progressed
more slowly [79]. Higher uric acid levels however,
though correlated with decreased risk [79], do not pro-
vide enough information to be pursued further as a pre-
motor PD biomarker. This is mostly due to the largely
non-specific action of uric acid as an anti-oxidant. Uric
acid levels are tightly controlled by the body and, most
importantly, while decreased risk may correlate with
higher levels of uric acid, PD can still develop despite
higher uric acid levels.
Similarly, the protein DJ-1 is expressed at high concen-
trations in cells and is thought to act as an antioxidant
[80,81] and interacts with many of the same proteins as
α-synuclein [82]. An initial study showed that DJ-1 is
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[83]. However, no significant differences between PD and
control groups were observed, nor was any correlation
with age. This initial study set the stage for future studies
examining the levels of DJ-1 in CSF and blood plasma.
Waragai et al. demonstrated several years ago that DJ-1
levels are increased in the plasma of PD patients [84].
The same group also showed an increase of DJ-1 in the
CSF of PD patients compared to control patients [85].
However, a more recent study has examined the levels of
DJ-1 in PD patient CSF and has come to the opposite
conclusion. It found that DJ-1 levels actually significantly
decreased in PD patient CSF using a highly sensitive
Luminex assay while at the same time controlling for
possible blood contamination of CSF, which can con-
found interpretation and reliability of results [55]. The
same group of investigators also concluded that in the
same cohort of patients and controls, while CSF DJ-1
levels decreased, plasma DJ-1 was largely unaltered [55].
Much like α-synuclein, the discrepancy among different
investigations is attributable to many issues, particularly
hemolysis [68]. As oxidized isoforms of DJ-1 are indica-
tive of increased oxidative stress [86-88], moving for-
ward, they should be explored along with total DJ-1 and
other promising biomarkers, in various body fluids, espe-
cially in the saliva of PD patients [73] or those with pre-
motor signs, thereby facilitating the development of
premotor biomarkers.
Neuroimaging
As technology has advanced in the past several decades,
it has allowed clinicians and researchers to acquire more
reliable and higher resolution data. Several techniques
are being investigated for their use as potential premotor
biomarkers [89]. Here, we will examine single-photon
emission computed tomography (SPECT), positron emis-
sion tomography (PET), and functional magnetic reson-
ance imaging (fMRI) (Table 1).
SPECT has been used for some time to image the
dopamine transporter (DAT). It has routinely established
a reduced binding in patients with PD [90] and can aid
clinicians in diagnosis and monitoring, as the decreased
ligand binding to the DAT correlates with disease pro-
gression and clinical scoring [91,92]. Although long term
pre-symptomatic screening with DAT SPECT for PD is
not particularly feasible due to high costs, limited access,
and general difficulty of working with radioactive tracers,
one group has shown it is useful for distinguishing be-
tween PD and other parkinsonian-like conditions [93].
Additionally, some PET imaging has shown reduced
binding of glucose in posterior parietal and cortical gray
matter of PD patients with dementia [94]. PET can also
be used as a highly sensitive measure to assess dopamine
uptake and binding to the DAT. Accordingly, PETimaging, which assesses radiolabeled ligands for DAT,
can be utilized to distinguish premotor PD [95,96]. Add-
itionally, fMRI is another potential neuroimaging modal-
ity for use as a premotor biomarker for PD. It has been
known almost a decade that whole brain atrophy is pre-
cipitated in PD versus controls and slightly less than in
Alzheimer’s disease [97]. More recent work has demon-
strated that irregularities in the substantia nigra of early
PD patients correlate with an increase in iron, which is a
known to be related to neuronal loss [98]. In addition,
one group has been able to provide 100% sensitivity and
specificity for differentiating PD patients from healthy
controls when imaging the caudal substantia nigra [99].
Another recent work has arrived at a 95% accuracy in
distinguishing PD from healthy controls using multi-
modal MRI of subcortical gray matter [100]. While fMRI
can successfully separate PD patients from controls, fur-
ther volumetric fMRI characterization of PD and related
disorders is currently underway and needed to provide
insight into whether fMRI can serve as an effective pre-
motor biomarker [101].
The neuroimaging markers reviewed all are able distin-
guish diseased PD patients from normal controls and
have the ability in some situations to identify probable
PD in premotor stages. However, their usefulness is lim-
ited due to issues of cost and availability, and, while they
may detect abnormalities associated with disease state,
they do not provide insight into molecular mechanism.
Their cost alone limits the ability of these tests to be
used widespread in a clinical diagnosis. Finally, the time
involved to acquire these neuroimages for both clinical
staff and patients is significant and cannot be overlooked
when considering potential premotor PD biomarkers.
Thus, it is likely that the structural/functional neuroima-
ging methods will be largely a research tool in the area
of biomarkers in the near future.
Genetic markers
Clearly, identification of premotor biomarkers first
requires identification of the population at risk. One ob-
vious choice is those with premotor signs, e.g. RBD and
constipation, an option which is, as previously discussed,
limited by the non-specific nature of these symptoms
prior to the onset of motor symptoms. Another possibil-
ity is to follow those with genetic mutations that lead to
familial PD. Thus, in the following section, we will ad-
dress the genetic mutations with a reasonable prevalence
for the purpose of premotor biomarker studies: parkin,
glucocerebrosidase (GBA), and leucine-rich repeat
kinase-2 (LRRK2).
While most idiopathic PD arises de novo and without
any known genetic mutation, the known genetic aberra-
tions which cause familial PD are invaluable in aiding
investigators to elucidate the pathways contributing to
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kers. Mutations in the parkin gene, which encodes a ubi-
quitin E3 ligase, results in enzymatic activity loss and
misfolding [102] and is responsible for the majority of ju-
venile, early-onset PD [103]. Parkin gene mutations may
serve as potential premotor biomarker as detecting this
mutation in the pre-symptomatic stages of the disease
will allow for the evaluation of relevant biomarkers in re-
lation to early-onset PD [104].
Another genetic mutation that has been associated
with PD is the gene encoding GBA. Mutations in GBA
cause Gaucher disease, which is the most common auto-
somal recessive lysosomal storage disease [105], and its
relationship with parkinsonism has been reviewed exten-
sively elsewhere [106]. PD and PD-like syndromes asso-
ciated with GBA mutations were first described in 1996
[107], and have subsequently been demonstrated to
occur at much higher frequencies in PD patients than
controls in pan-ethnic populations from Israel [108,109],
Italy [110], China [111,112], North Africa [113], Great
Britain [114], Europe [115], and the United States
[116,117]. In fact, a large 16-center, multi-country ana-
lysis, 15% of Ashkenazi Jewish PD patients had one of
two of the most common GBA mutations compared to
3% of controls [118]. Furthermore, in almost 2000 non-Figure 2 The Search for Premotor PD Biomarkers. 1. In order to discove
population more likely to develop PD. Patients with genetic susceptibility m
biomarkers, hyposmia, RBD, constipation, and depression. 2. Patients with g
neuroimaging changes known to correlate with PD. 3. After verification wit
biochemical markers has already been verified will be acquired (blood, CSF
identification will use changes in the levels of known biochemical markers,
unbiased profiling.Jewish PD patients, 7% tested positive for GBA muta-
tions after full sequencing of the gene and concluded
that patients with GBA mutations present with an earlier
onset of PD symptoms [118]. Most promisingly, these
pan-ethnic population studies are just beginning to be
supported by mechanistic studies. For example, one
group recently demonstrated that in PD patients with
GBA mutations, an average of 75% of Lewy Bodies exam-
ined were positive for GBA [119]. Others have shown
that GBA mutants can raise the levels of α-synuclein
in vitro and that the amassing of α-synuclein was
reversed by activation of autophagy pathways [120].
Moreover, α-synuclein and GBA’s interaction takes place
optimally under pH conditions like those in the lysosome
[121], thereby further linking PD pathology with to GBA
function. Thus, GBA mutations represent an increased
risk for PD development and add additional evidence to
a genetic component to the disease.
Mutations in another gene, LRRK2, are probably
among the most studied. In contrast to parkin muta-
tions, LRRK2 mutations result in an autosomal dominant
form of PD that closely resembles idiopathic PD. LRRK2
mutations account for about 1-2% of sporadic PD cases
worldwide, but in genetically isolated populations, such
as Ashkenazi Jews and North African Arabs, ther premotor PD biomarkers, it is necessary to first enrich for patient
arkers, for example, parkin and LRRK2 mutations, and clinical
enetic markers and clinical phenotypes will undergo screening for
h neuroimaging, various patient tissues where the presence of
, saliva, and skin). 4. Premotor PD biomarker assessment and
i.e., α-synuclein, uric acid, DJ-1, in addition to others identified through
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adic and familial PD cases [122-127]. The most common
mutation is G2019S, which produces a constitutively ac-
tive kinase [128]. Recent evidence points to LRRK2 in-
volvement in dopaminergic neuron transmission further
linking the gene to PD [129]. Additionally, another re-
cent study examined the downstream targets of LRRK2
and found that α-synuclein is phosphorylated by LRRK2,
further implicating α-synuclein in both familial and spor-
adic PD [130]. This led our group to examine a cohort of
symptomatic and asymptomatic LRRK2 mutation car-
riers. Because of the high conversion rate of LRRK2 mu-
tation carriers to clinical disease, this patient population
presents a unique subset of PD patients in which evalu-
ation of symptoms and biomarkers can occur decades
before clinical signs appear. One of our recent studies
attempted to correlate dopaminergic function with both
DJ-1 and α-synuclein levels in LRRK2 mutation carrier
CSF. The major finding of this study was that no appar-
ent relationship existed between dopaminergic loss and
levels of DJ-1 and α-synuclein in patient CSF [131]. An-
other recent publication resulting from the same patient
cohort [131] investigated LRRK2 mutation carriers for
the levels of amyloid β-42 (Aβ42) and tau in patient CSF
[132]. We found that LRRK2 mutation carriers showed
reduced CSF Aβ42 and tau levels that correlated with
lower dopaminergic neuron function as determined by
PET tracer [132]. These findings elucidate the possible
role DJ-1, α-synuclein, Aβ42, and tau in premotor PD
and provide insight into which direction future premotor
PD biomarker studies might take.
Other researchers have been able to differentiate
between LRRK2 PD patients and their healthy family
members with or without LRRK2 mutations using meta-
bolomic profiling of LRRK2-PD, LRRK2-mutation car-
riers, control, and idiopathic PD patients [133]. Another
group was also able to distinguish between asymptomatic
carriers of LRRK2 mutations and healthy carriers by
measuring gait alterations [134]. They found that there
were significant differences in gait variability measures
under three different gait conditions [134] leaving open
the possibility that motor symptoms might appear earlier
than previously thought. Taken together, these genetic
populations that have a high conversion rate from asymp-
tomatic to PD provide a unique cohort of patients to help
validate other biomarker discoveries. As these patients
can easily be followed in a longitudinal fashion, examin-
ing clinical presentation along with biological fluids and
assessing them for PD biomarkers will be key in develop-
ing our understanding of biomarkers, disease progression,
and possible disease interventions (Figure 2). Structural
and functional neuroimaging methods will be certainly
helpful in determining whether an asymptomatic subject
is at premotor stage or not.In addition to LRRK2 and parkin mutations, the use-
fulness of having a genetic marker as an a priori identi-
fier of at-risk populations has led to attempts to identify
other loci associated with PD. Several groups have com-
pleted independent genome-wide association studies for
PD but have had inconsistent results [135-137]. How-
ever, two loci previously associated with neurodegenera-
tive disease, SNCA (encoding α-synuclein) and MAPT
(encoding tau), have been reproducibly implicated in sev-
eral studies, strongly suggesting a role for both in PD
pathogenesis [138-143]. However, PD generation appears
to be a complex process requiring the interactions of
multiple genetic and environmental factors, so the iden-
tification of high-risk groups, prior to the emergence of
motor symptoms, remains a significant problem, until a
robust premotor biomarker can be found in an easily ac-
cessible sample source.
Conclusions
The need to develop premotor PD biomarkers is increas-
ingly apparent as the aging population grows and consider-
ing the limited effectiveness of neuroprotective treatments
in altering disease course at the advanced stages. The clin-
ical biomarkers have been well-characterized and correlated
with PD outcomes and severity but tend to lack specificity
and sensitivity. Neuroimaging, however, can be highly sensi-
tive and specific for premotor PD but significant cost and
access barriers exist. The most promising avenue for future
work involves both genetic markers and biochemical mar-
kers, and currently, efforts are underway at several sites
worldwide, including the Michael J. Fox Foundation (http://
www.michaeljfox.org/research_MJFFresearchTools.cfm) and
the Parkinson’s UK Brain Bank (www.parkinsons.org.uk/),
to collect and utilize PD tissues to this end [144]. Because
some genetically susceptible populations, such as LRRK2 or
GBA mutation carriers, possess known PD-associated
mutations, they can be employed to validate and screen po-
tential biochemical markers underutilized biological sam-
ples, such as saliva. In short, the best outlook for premotor
PD biomarkers relies heavily on the rapid and reliable iden-
tification of premotor biomarkers with independent valid-
ation of biochemical markers the clinical cohort most likely
to develop PD.
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